Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $12,128.88 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 291 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $12,128.88. Following the sale, the senior vice president now owns 130,621 shares of the company’s stock, valued at $5,444,283.28. The trade was a 0.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Paula Green also recently made the following trade(s):

• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38.
• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $7,294.40.

Twist Bioscience Stock Down 5.4 %

TWST stock opened at $41.88 on Thursday. The company has a market capitalization of $2.50 billion, a P/E ratio of -12.39 and a beta of 2.15. The firm has a 50 day simple moving average of $45.38 and a 200-day simple moving average of $45.34. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period last year, the business earned ($0.75) EPS. On average, equities research analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC bought a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $714,000. Massachusetts Financial Services Co. MA increased its stake in Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after purchasing an additional 20,035 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Twist Bioscience by 4.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company’s stock worth $23,717,000 after purchasing an additional 24,582 shares during the period. Algert Global LLC lifted its position in shares of Twist Bioscience by 59.7% in the 3rd quarter. Algert Global LLC now owns 43,592 shares of the company’s stock worth $1,969,000 after buying an additional 16,292 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Twist Bioscience in the 3rd quarter valued at about $599,000.

Wall Street Analysts Forecast Growth

Several research analysts have commented on TWST shares. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an “overweight” rating in a research report on Monday, February 3rd. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Finally, Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.